Important note: Information in this article was accurate in May 2005. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - Vol. 6, No. 5, May 2005
Polly Clayden, HIV i-Base
Lopinavir/ritonavir is increasingly recommended for treating young infants but in the absence of published data. Ellen Chadwick and colleagues from the PACTG 1030 study group evaluated dose requirements for babies <6 months that provide systemic exposure similar to that which has been shown to be safe and effective in older children and adults.
Results were available for 12 infants (5 boys, 7 girls) and stratified by age: 14 days to 6 weeks and 6 weeks to 6 months. A dose of 300 mg/m2 lopinavir/ 75mg/m2 ritonavir was studied in combination with two nucleosides.
Intensive PK studies were performed at two weeks with a dose adjustment if LPV/r 12-hour post-dose concentration (C12) was < 1 mg/L; C12 was measured every 12 weeks and intensive pharmacokinetic studies were repeated if there was dose adjustment at one year of age.
The study defined virologic success as viral load < 400 copies/mL at week 16; failure as never achieving < 400 copies/mL and late suppressors as achieving < 400 copies/mL after week 16. CD4 percentage was measured every 12 weeks.
Median follow-up at analysis was 50 weeks (range 19 to 112 weeks). At entry, median age was 9.4 weeks (range 3.6 to 25.7 weeks), log10 HIV-1 RNA 5.6 (3.77 to 6.88) and CD4 percentage 37% (19 to 59%). Six of the 12 infants (50%) had virologic success, 2 (17%) virologic failure, and 4 (34%) were defined as late suppressors (< 400 copies/mL at week 32 to 48). The authors noted that poorer adherence contributed to poorer response.
In 6 infants studied through week 36, CD4 percentage showed a median increase of 8% (–9 to +20%) from baseline.
One infant required dose adjustment. Infants with virologic success vs virologic failure/late suppressors were significantly younger (median 5.6 vs 15.9 weeks, p = 0.004).
The authors found that the dose of 300 mg/m2 LPV/r twice daily was well tolerated in young infants and produced encouraging results in those infants adherent to therapy. At week 2 lower plasma concentrations were reported than found in adults despite a surface area adjusted dose approximately 35% higher than recommended for adults.
To better define age-related differences in pharmacokinetics and response to LPV/r, this group will study a second cohort of 12 infants.
050510
IB050605-09
©2005. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone / Firestone Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
